Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase IV Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2017
Price : $35 *
At a glance
- Drugs PG 201 (Primary) ; Nabumetone
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors PMG Pharm Co Ltd
- 17 Sep 2017 Status changed from recruiting to completed.
- 02 Jul 2014 New trial record